Drugs in Dev. Sleep
Phase IV
Lead Product(s) : Chloral Hydrate
Therapeutic Area : Sleep
Study Phase : Phase IV
Sponsor : Lindus Health
Deal Size : Not Applicable
Deal Type : Not Applicable
Pharmanovia Study Shows Chloral Hydrate Improves Severe Insomnia Within Two Weeks
Details : Chloral hydrate is converted rapidly to trichloroethanol, which is largely responsible for its hypnotic action. It is indicated for the treatment for severe insomnia.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 01, 2024
Lead Product(s) : Chloral Hydrate
Therapeutic Area : Sleep
Highest Development Status : Phase IV
Sponsor : Lindus Health
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Solriamfetol Hydrochloride
Therapeutic Area : Sleep
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Sunosi (solriamfetol) is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA).
Brand Name : Sunosi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 07, 2022
Lead Product(s) : Solriamfetol Hydrochloride
Therapeutic Area : Sleep
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
